Serum exosomal tsRNA biomarkers: A novel strategy for identifying lupus nephritis

作者：Ping Yang, Yifan Sun, Chenlan Wang, Zhibo Li, Zhibo Li, Yiyuan Han, Gong Jianming, Adeel Khan, Jin Wang, Yanbo Wang, Fangfang Jin, Zhiyang Li, Zhiyang Li · 发表于：Clinical and Translational Medicine · 年份：2024 · DOI：10.1002/ctm2.1677 · 被引用次数：11 · 研究领域：Systemic Lupus Erythematosus Research、Extracellular vesicles in disease、Atherosclerosis and Cardiovascular Diseases

Dear Editor, For effective treatment and control of systemic lupus erythematosus (SLE), it is pertinent to be able to precisely identify and predict lupus nephritis (LN).1 The current gold standard for this is renal biopsy, but this is invasive, making it less attractive for dynamic monitoring of disease progression.2, 3 tRNA-derived small non-coding RNAs (tsRNAs), as a novel RNA biomarker, intricately involved in regulating various stages of gene expression, from transcription, translation, RNA processing, to maturation, are implicated in key cellular processes, including self-renewal, differentiation, proliferation and onset of pathological conditions such as immune system disorders and cancer.4-7 Exosomes, which typically range from 30 to 100 nm, derived from cells, serve as pivotal mediators for intercellular communication and also act as crucial carriers for circulating tsRNA.8 Here, we anticipated and demonstrated that serum exosome-encapsulated tsRNAs can serve as biomarkers for executing LN diagnosis noninvasively. The study recruited participants (HC, n = 80; SLE (LN‒), n = 122; LN, n = 131) from Nanjing Drum Tower Hospital between September 2020 and June 2022, in accordance with the 1997 SLE classification criteria9 set by the Rheumatology Society (Table 1). Ethical approval was obtained from the Ethics Committee of Nanjing Drum Tower Hospital, with the approval identification number 2020-327-01. An exosome isolation kit (from serum) (Thermo Fisher Scientific Inc.) ...